Novartis has presented new data showing that its biologic Cosentyx reduced signs and symptoms of psoriatic arthritis (PsA) while inhibiting progression of joint structural damage.
News
Speedy review for Jazz’ high-risk AML chemo
Dublin, Ireland-based Jazz Pharmaceuticals’ Vyxeos is being given a speedy review in Europe as a treatment for certain types of high-risk acute myeloid leukemia (AML).
GSK’s R&D chief to leave for UK gov role?
GlaxoSmithKline’s head of R&D Patrick Vallance is reportedly leaving the firm to take on the role of chief scientific advisor at the government.
Novartis files CAR-T therapy in Europe
Novartis has submitted an application to the European Medicines Agency for its CAR-T therapy CTL019 for two haematological indications.
Merck, Pfizer launch Bavencio for rare skin cancer
Merck and Pfizer have launched in the UK of Bavencio, the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).
Clive Myrie to interview special guest at Marketer & Communications Team of the Year Awards
Renowned journalist and news anchor Clive Myrie is to interview Chloe Brown, a project worker at Investing in Children (IiC) CiC live on stage at next week’s PharmaTimes Marketer & Communications Team of the Year Awards.
Government unveils plans to accelerate access to medicine
The government has finally published its long-awaited response to the Accelerated Access Review, with plans for a new Accelerated Access Pathway that will open a new channel providing patients with faster access to the most innovative medicines and technologies.
Novartis, Amgen, BAI start new Alzheimer’s prevention study
Novartis, Amgen and the Banner Alzheimer’s Institute (BAI) have expanded their collaboration to initiate a new study investigating BACE1 inhibitor CNP520 can prevent or delay the onset of Alzheimer’s disease symptoms in a high-risk population.
BI, Dicerna to develop RNAi therapeutics for liver disease
Boehringer Ingelheim has linked with US group Dicerna Pharmaceuticals to develop new RNAi therapeutics for liver diseases.
UK children experiencing chronic delays in ADHD diagnosis
Young people in the UK with ADHD are at “serious risk of social and mental health harm” because they experience some of the “longest and most complicated” delays to diagnosis anywhere in Europe, a group of experts is warning.
‘Breakthrough’ tag for GSK’s multiple myeloma drug
An investigational antibody-drug conjugate being developed by GlaxoSmithKline for patients with multiple myeloma has been awarded Breakthrough Therapy Designation from the US Food and Drug Administration.
AZ’ experimental asthma drug fails in Phase III
An experimental therapy being developed by AstraZeneca and its biologics research and development arm MedImmune has failed to hit key targets in two Phase III trials.
Final NICE nod for Sanofi’s Kevzara
The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as a new treatment option for adults with severe, active rheumatoid arthritis (RA).
GSK’s Anoro Ellipta beats BI’s Spiolto Respimat in COPD trial
GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s Spiolto Respimat.
EU OKs low-dose Xarelto to prevent recurrent VTE
A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
